Work

A phase 1b/2 study of AK130 (TIGIT/TGF-β bispecific fusion protein) combined with ivonescimab in advanced biliary tract cancer (BTC).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.4142

Authors: Haitao Zhao, Tongsen Zheng, Xiaobo Yang, Caiqi Liu, Jinxue Zhou, Hong Zhao, Zhitian Shi, Jianfei Fu, Zhongtao Zhang, Enxiao LI, Houbao Liu, Wenting Li, Baiyong Li, Michelle Y. Xia

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Third Affiliated Hospital of Harbin Medical University, Henan Cancer Hospital, Kunming Medical University, Jinhua Central Hospital, Capital Medical University, Beijing Friendship Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Fudan University, Zhongshan Hospital

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162498976

Cites:

Cited by:

Related to: